Comparison Between Maternal Blood Glucose and Fetal Cord Insulin Level Among Gestational Diabetes Mellitus Women

C.S. Brethis1, R. Hemalatha2*, Ramyaa Rajendiran3, Sumitha A1, Navneeth P1 and Amalnath A1

1Department of Pharmacology, ACS Medical College and Hospital, Chennai, India.
2Department of Biochemistry, Saveetha Medical College, Chennai, India.
3Department of Pediatrics, Tagore Medical College and Hospital, Chennai, India.
*Corresponding Author E-mail: hemalathaaramar@gmail.com

https://dx.doi.org/10.13005/bpj/2689
(Received: 26 August 2022; accepted: 09 January 2023)

Offspring of gestational diabetes mellitus (GDM) mothers are at high risk of developing insulin resistance, type 2 diabetes mellitus (T2 DM), and cardiovascular complications later in life. So, screening maternal blood glucose during pregnancy and identifying high-risk infants immediately after birth is necessary to prevent the potential long-term implications. To correlate the maternal fasting and post-prandial blood glucose with fetal insulin level. A case-control study, was conducted at Chettinad Hospital and Research Institute, India, between May 2019 to May 2020. A 75-gram OGTT was performed among pregnant women between 24 to 28 weeks of pregnancy for diagnosing GDM according to American Diabetes Association (ADA) guidelines. 94 GDM mothers and Non-GDM mothers and their new-borns were taken up for this study. 2.5ml of maternal venous blood was collected in a vacutainer containing sodium fluoride and EDTA as an anticoagulant for FBS and PPBS estimation. Some mothers on induction of labor were posted for emergency LSCS (for failed induction and non - progression of labor) and some had normal vaginal deliveries. Plasma FBS and PPBS estimation in the mother’s blood sample was assayed by the Hexokinase method in Siemens Dimension RxLMachine immediately after centrifugation. 2.5ml of umbilical cord blood was collected in a vacutainer without an anticoagulant after the 2nd stage of labor. 0.5 ml of cord blood serum was separated and stored at -80°C in an eppendorf for later estimation of insulin by CLIA method in Beckman Coulter – Access 2 Immunoassay System. Independent students’ t-tests and Pearson's correlation were used as statistical methods. p-value <0.05 is considered significant. There is a positive correlation and significant difference between maternal FBS, PPBS, and fetal insulin levels in the GDM group (p-value 0.008, r-value 0.272 and p-value 0.005, r-value 0.286) compared to the Non-GDM group (p-value -0.087, r-value 0.243 and p-value 0.018, r-value 0.212). Significant hyperinsulinemia was noted in the offspring of the GDM group compared to the NON-GDM group. Those hyper-insulinemic babies are at very high risk of developing obesity, metabolic syndrome, and type 2 DM in the future and possess a threat to society.

Keywords: APGAR score; Fetal cord insulin; FBS; Gestational Diabetes mellitus; PPBS; Placenta weight.
their intrauterine environment have an impact on their offspring’s health throughout their lifespan after their birth. The emerging field of the developmental origins of health and disease (DOHAD) states that the intrauterine and early neonatal periods have a permanent programming effect on the body’s metabolism and health later in life. The most common physiological alteration during pregnancy is gestational diabetes mellitus (GDM). GDM is defined as the varying degree of glucose intolerance that is diagnosed first during pregnancy. Though the underlying pathophysiology of GDM is not fully understood, it has been thought that the hormonal imbalances in the mother could affect the pancreas and lead to á-cell dysfunction and insulin sensitivity in their offspring. In a random survey prevalence of GDM is known to be 3.8 to 21% in India and 16.2% in Chennai urban population. The occurrence of GDM in pregnant women and its complications in the newborn can be overcome by proper management of blood sugar levels during the perinatal, and postnatal periods.

The degree of maternal insulin resistance established during pregnancy is associated with the degree of glucose flux from the mother to the fetus. During pregnancy 30% of hepatic glucose production increases as fetal development depends on the maternal metabolic profile throughout the whole pregnancy period, illustrated by the fact that obese women or women who develop gestational diabetes have larger fetuses already by 20 weeks of gestation. Maternal hyperglycemia leads to fetal hyperglycemia and hyperinsulinemia, which causes fetal macrosomia as one of the most common and serious complications of maternal GDM. This may be a predisposing factor for newborns of GDM mothers to develop metabolic syndrome and T2DM in future. This vicious cycle would increase the incidence and prevalence of GDM. Failure to treat the elevated blood sugar levels before and during pregnancy might end up in complications like preterm delivery, caesarean section, big babies, serious complications in new-borns, and raised bilirubin levels. Many studies have indicated the association of GDM with macrosomia and other birth defects.

Based on this hypothesis, maternal endocrine parameters can cause obesity, metabolic syndrome, and T2DM in GDM mother’s offspring in the future. So, assessment of fetal insulin at birth will be a very sensitive parameter and will reveal the maternal hyperglycemic insult in utero and create an awareness of the risks of GDM in future. However, there is a dearth of such case-control studies to demonstrate the association of maternal parameters affecting the fetus in utero. So, this study was planned to correlate the fasting and postprandial blood glucose of GDM and NON-GDM mother with their fetal insulin levels and to identify the high-risk offspring as early as possible in order to create awareness of the risks of GDM in the fetus.

**Aim & Objective**

**Primary**

To correlate the fasting and postprandial blood glucose of GDM and NON-GDM mothers with their fetal insulin levels.

**Secondary**

- To identify the high-risk babies as early as possible.
- To create awareness of the risk of GDM in fetuses.

**METHODS**

**Study design & population**

This is a single-center case-control study conducted at Chettinad Hospital and Research Institute, India, between May 2019 to May 2020 after obtaining clearance from the Institutional Human Ethics Committee. **Inclusion criteria:** Pregnant women between 18-45 years, 37 – 40 weeks of gestation, height between 157-161 cms, pregnancy weight during 1st trimester between 58 -65 kgs, pregnancy BMI during 1st trimester between 20 – 25 kg/m²GDM confirmed between 24-28 weeks (OGTT) and GDM on dietary management with the meal plan, pregnancy weight at term between 75-85 kgs, pregnancy BMI at term 25-30 kg/m² were included in the study. **Exclusion criteria:** Previously known cases of Diabetes Mellitus(DM), GDM women on insulin and insulin secretagogues, major medical or surgical history in the past, anomalous fetus in present pregnancy, pregnancy-induced hypertension - PIH /pre-eclampsia/eclampsia, blood transfusion in present pregnancy, pregnant women on corticosteroids and antenatal corticosteroids given in last 3 days were excluded from the study.
Sample Size
The size was calculated using the following formula,
\[ \hat{\sigma}^2 = \frac{(n-1)s^2}{\hat{\sigma}^2} \]
sample size(n) = 188, standard deviation (\(\hat{\sigma}\))= 46, level of statistical significance (\(z_\alpha\)) = 1.96,
desired power (\(z_\beta\)), desired power = 0.84, difference in mean (\(d^2\)) = 10. 94 GDM women and their newborns and 94 Non-GDM women and their newborns were taken up for this study.

Data Collection
A 75-gram OGTT was performed after 8 hours of overnight fasting in a pregnant woman without previous history of DM between 24 to 28 weeks and the plasma glucose is measured at fasting, 1st and 2nd hour. Informed consent was obtained from the antenatal women who were admitted for induction of labor and for elective LSCS. 2.5ml of maternal venous blood was collected in a vacutainer containing sodium fluoride and EDTA as an anticoagulant for FBS and PPBS estimation. Some patients on induction of labor were posted for emergency LSCS (for failed induction and non - progression of labor) and some had normal vaginal deliveries. Plasma FBS and PPBS estimation in the mother’s blood sample was done by the Hexokinase method in Siemens’Dimension RXLMachine immediately after centrifugation. 2.5ml of umbilical cord blood was collected in a vacutainer without an anticoagulant after the 2nd stage of labor. Cord blood was centrifuged immediately and 0.5 ml of serum was separated and stored at -80°C in an Eppendorf for later estimation of insulin. Estimation of serum insulin was done by CLIA method in Beckman Coulter – Access 2 Immunoassay System.

Definition of GDM and Fetal hyperinsulinemia
The diagnosis of GDM between 24-28 weeks of pregnancy was concluded when any one of the following glucose values are met or exceeded according to American Diabetes Association (ADA): Fasting blood glucose: 95 mg

---

**Table 1. Comparison of Demographic Variables Between GDM and Non-GDM mothers and Their New-borns by Independent student’s t-test**

<table>
<thead>
<tr>
<th>S.No</th>
<th>Category</th>
<th>GDM</th>
<th>NON-GDM</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Maternal age(years)</td>
<td>24.61 ± 4.06</td>
<td>23.98 ± 3.37</td>
<td>0.003</td>
</tr>
<tr>
<td>2.</td>
<td>Gestational Age (weeks)</td>
<td>37.84 ± 3.76</td>
<td>42.39 ± 37.29</td>
<td>0.241</td>
</tr>
<tr>
<td>3.</td>
<td>Maternal height (cms)</td>
<td>159.83 ± 2.39</td>
<td>158.72 ± 2.27</td>
<td>1.000</td>
</tr>
<tr>
<td>4.</td>
<td>Pregnancy weight (kgs) during 1st trimester</td>
<td>64.36 ± 5.39</td>
<td>64.36 ± 5.34</td>
<td>1.000</td>
</tr>
<tr>
<td>5.</td>
<td>Pregnancy BMI (kg/m²) during 1st trimester</td>
<td>24.21 ± 2.83</td>
<td>20.92 ± 2.03</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>6.</td>
<td>Pregnancy weight at term (kgs)</td>
<td>76.44 ± 5.35</td>
<td>85.67 ± 4.36</td>
<td>1.000</td>
</tr>
<tr>
<td>7.</td>
<td>Pregnancy BMI at term (kg/m²)</td>
<td>29.66 ± 2.38</td>
<td>24.62 ± 2.10</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>8.</td>
<td>Maternal FBS before delivery (mg/dL)</td>
<td>91.52 ± 7.99</td>
<td>84.00 ± 8.24</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>9.</td>
<td>Maternal PPBS before delivery (mg/dL)</td>
<td>148.62 ± 13.72</td>
<td>122.90 ± 6.26</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>10.</td>
<td>Fetal insulin (µIU/L)</td>
<td>24.97 ± 19.36</td>
<td>5.25 ± 6.50</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>11.</td>
<td>Baby Weight (kgs)</td>
<td>3.35 ± 0.33</td>
<td>2.96 ± 0.27</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>12.</td>
<td>Placenta weight (grams)</td>
<td>497.68 ± 4.27</td>
<td>489.72 ± 3.97</td>
<td>1.000</td>
</tr>
<tr>
<td>13.</td>
<td>APGAR score in 1 Minute</td>
<td>7.69 ± 0.58</td>
<td>7.91 ± 0.28</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>14.</td>
<td>APGAR score in 5 Minutes</td>
<td>8.80 ± 0.43</td>
<td>8.91 ± 0.28</td>
<td>0.028</td>
</tr>
</tbody>
</table>

Abbreviations: BMI – Body Mass Index; FBS - Fasting Blood Glucose; PPBS - Postprandial Blood Glucose; APGAR – Appearance, Pulse, Grimace, Activity, and Respiration.
Continuous variables are described using mean ± standard deviation
p-value < 0.05 is considered significant.

**Table 2. Correlation Between Maternal Blood Glucose and Fetal Insulin in GDM Women by Pearson’s Correlation**

<table>
<thead>
<tr>
<th>Maternal parameter</th>
<th>Fetal insulin (µIU/L)</th>
<th>r value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS (mg/dL)</td>
<td>0.272</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>PPBS (mg/dL)</td>
<td>0.286</td>
<td>0.005</td>
<td></td>
</tr>
</tbody>
</table>

p-value < 0.05 is considered significant
per dL, 1st hr: 180 mg per dL, 2nd hr 153 mg per dL. Plasma FBS >95 mg/dL and PPBS >140 mg/dL were considered high values before labor. The normal umbilical cord insulin level is <13 µIU/L and levels > 13 µIU/L is considered fetal hyperinsulinemia.

**Statistical Results & Analysis**

**Characteristics of study participants**

The study included 94 GDM mothers and their new-borns (Group 1) and 94 Non-GDM mothers and their offspring (Group 2). The comparison of demographic variables of GDM and Non-GDM mothers and their offspring (Group 2) was performed.
Table 3. Correlation Between Maternal Blood Glucose and Fetal Insulin in Non-GDM Women by Pearson’s Correlation

<table>
<thead>
<tr>
<th>Maternal parameter</th>
<th>Fetal insulin (µIU/L)</th>
<th>r-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS (mg/dL)</td>
<td>-0.087</td>
<td>0.243</td>
<td></td>
</tr>
<tr>
<td>PPBS (mg/dL)</td>
<td>0.212</td>
<td>0.018</td>
<td></td>
</tr>
</tbody>
</table>

p-value < 0.05 is considered significant

Fig. 3. Correlation Between Maternal FBS and Fetal Insulin level in the Non-GDM Group

maternal BMI at term (29.66 ± 2.38 vs 24.62 ± 2.10, p-value < 0.001), fetal umbilical cord insulin (24.97 ± 19.36 vs 5.25 ± 6.50, p < 0.001), baby weight (3.35 ± 36.58 vs 2.96 ± 0.27, p < 0.001), 1 minute APGAR score (7.69 ± 0.58 vs 7.91 ± 0.28, p < 0.001) and 5 minutes APGAR score (8.80 ± 0.43 vs 8.91 ± 0.28, p < 0.028) between the 2 groups.

Correlation Between Maternal Blood Glucose and Fetal Insulin Levels in Both the GDM and Non-GDM Groups

Maternal FBS and PPBS in the GDM group showed a positive correlation with fetalumbilical cord insulin levels with r-value of 0.272 (p-value 0.008) and r-value of 0.286 (p-value 0.005).

Maternal FBS and PPBS in the Non-GDM group showed a positive correlation with fetalumbilical cord Insulin levels with r-value of -0.087 (p-value 0.243) and r-value of 0.212 (p-value 0.018).

DISCUSSION

Insulin resistance and deficiency in adults is highly related to the incidence of GDM17. Several studies on GDM have reported on the metabolic abnormalities of GDM mothers. Quite a few focused on maternal-fetal metabolic mechanisms in pregnant women with GDM 18. Our study tried to determine the effect of GDM on fetal insulin resistance. We found that Maternal FBS and PPBS in the Non-GDM group showed a positive correlation with fetal umbilical cord Insulin levels.
The mechanism that gives an explanation for the hyper insulin levels in the fetuses of GDM mothers is the hyperactivity in the fetal â-cell mass since maternal blood glucose is a critical stimulator of fetal â-cell hyperplasia 19. The pancreatic â-cell hyperplasia cited inside the pancreas of a newborn child from a GDM mother demonstrated that during the early fetal period, the proliferative potential of the â-cell is very excessive 20. Neonatal hyperinsulinemia in association with neonatal hypoglycemia is a marker of the above-mentioned mechanism. This is an energetic process during the early neonatal period and additionally during adolescence, puberty and childhood. At around two decades of life, when the â-cells of the fetus arrive at the post-mitotic stage their ability for replication is almost impossible and leads to T2DM. In order to break the such vicious cycle, it is wise to improve maternal glycemic control during pregnancy itself21. A study conducted by Wang et al., and Arshad et al., explains the anabolic effect of insulin is thought to contribute to increasing fetal adipocyte mass and placental tissues in utero that are liable to change with maternal metabolic parameters. There is fetal â-cell hypertrophy and hyperplasia with excessive circulating insulin levels in the serum which upregulates the expression of many genes, leptin, and inflammatory cytokines levels in the placenta leading to fetal macrosomia and placental volume which compensates for the high demands of the growing fetus in utero to an extent. Thereafter, fetal hypoxia ensues leading to unexplained maternal and fetal adverse outcomes 22,23. Dabelea et al., and Desoye et al., states that intrauterine exposure to high maternal blood glucose is associated with fetal hyperinsulinemia, obesity, and T2DM in the offspring in the future. Maternal hyperinsulinemia through its own effect on lowering maternal hyperglycemia, will increase the glucose passage across the placenta and therefore the influx of glucose towards the fetus. The apparent documentation is that maternal glycemic control should be optimized very early during pregnancy to avoid fetal hyperinsulinemia 24,25.

CONCLUSION

In summary, GDM and fetal hyperinsulinemia are associated with the long-term development of obesity, and diabetes mellitus in the offspring, involving deleterious mechanisms of intrauterine programming. Our results suggest a positive correlation between maternal plasma
blood glucose and fetal insulin levels with clear statistical evidence of metabolic programming during pregnancy which would help to identify high-risk babies early and to create awareness about GDM and its complications.

**Strengths of the study**
- It is a case-control study.
- Maternal and fetal parameters were correlated.
- Timed collection and storage of cord blood samples.
- Fetal cord blood insulin was assayed which is more sensitive than venous blood.
- Fetal cord insulin was assayed by CLIA method.

**Limitations**
- HOMA-IR using C-peptide for both mothers and new-born was not evaluated.
- The present study is done in a single centre.

**Conflict of Interest**
No conflict of interest.

**REFERENCES**


